Patents Assigned to CERTA THERAPEUTICS PTY LTD.
  • Solid forms, salts and polymorphs of anti-fibrotic compounds
    Patent number: 11905231
    Abstract: The present disclosure relates to solid forms and salts, crystalline and otherwise, of (E)-2-[[3-(3-methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid and pharmaceutical compositions comprising same. The use of such solid forms, salts, and pharmaceutical compositions, for treating, preventing, or ameliorating diseases or conditions associated with fibrosis, inflammation and/or proliferation are disclosed.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: February 20, 2024
    Assignee: Certa Therapeutics Pty Ltd
    Inventors: Darren James Kelly, Gareth Rhys Lewis, Lorna Helen Mitchell
  • Anti-fibrotic compounds
    Patent number: 11603349
    Abstract: Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: March 14, 2023
    Assignee: Certa Therapeutics Pty Ltd
    Inventors: Thomas Miller, Nikolaos Papaioannou
  • ANTI-FIBROTIC COMPOUNDS
    Publication number: 20210246100
    Abstract: Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.
    Type: Application
    Filed: April 12, 2021
    Publication date: August 12, 2021
    Applicant: Certa Therapeutics Pty Ltd
    Inventors: Thomas Miller, Nikolaos Papaioannou
  • Anti-fibrotic compounds
    Patent number: 11014873
    Abstract: Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 25, 2021
    Assignee: CERTA THERAPEUTICS PTY LTD.
    Inventors: Thomas Miller, Nikolaos Papaioannou